79 related articles for article (PubMed ID: 321117)
1. Effects of methanol extraction residue of Bacillus calmette-Guérin in humans.
Perloff M; Holland JF; Lumb GJ; Bekesi JG
Cancer Res; 1977 Apr; 37(4):1191-6. PubMed ID: 321117
[TBL] [Abstract][Full Text] [Related]
2. Clinical studies of methanol extraction residue fraction of Bacillus Calmette-Guérin as an immunostimulant in patients with advanced cancer.
Moertel CG; Ritts RE; Schutt AJ; Hahn RG
Cancer Res; 1975 Nov; 35(11 Pt 1):3075-83. PubMed ID: 1102082
[TBL] [Abstract][Full Text] [Related]
3. The methanol extract residue (MER) of bacillus calmette-guerin in cancer immunotherapy.
Domenick NP
Nurs Clin North Am; 1978 Jun; 13(2):369-80. PubMed ID: 353752
[No Abstract] [Full Text] [Related]
4. Phase I study of iv administration of methanol extraction residue of Bacillus Calmette-Guérin.
Vogl SE; Perloff M; Kaplan BH; Holland JF
Cancer Treat Rep; 1979; 63(11-12):2039-41. PubMed ID: 393387
[TBL] [Abstract][Full Text] [Related]
5. Effects of methanol extraction residue and therapeutic irradiation against established isografts and simulated local recurrence of mammary carcinomas.
Yron I; Cohen D; Robinson E; Haber M; Weiss DW
Cancer Res; 1975 Jul; 35(7):1779-90. PubMed ID: 1093676
[TBL] [Abstract][Full Text] [Related]
6. Combined-modality treatment of inoperable lung cancer (i.v. immunotherapy, chemotherapy, and radiotherapy).
Robinson E; Haim N; Segal R; Veseley Z; Mekori T
Cancer Treat Rep; 1985 Mar; 69(3):251-8. PubMed ID: 2983892
[TBL] [Abstract][Full Text] [Related]
7. A comparative clinical and immunological assessment of methanol extraction residue of Bacillus Calmette-Guérin versus placebo in patients with advanced cancer.
O'Connell MJ; Moertel CG; Ritts RE; Frytak S; Reitemeier RJ
Cancer Res; 1979 Sep; 39(9):3720-4. PubMed ID: 383287
[TBL] [Abstract][Full Text] [Related]
8. Methanol extraction residue fraction of tubercle bacilli (MER) and other mycobacterial extracts as systemic immunity adjuvants in cancer immunotherapy.
Mathé G; Hiu IJ; Halle-Pannenko O; Bourut C
Isr J Med Sci; 1976; 12(4-5):468-71. PubMed ID: 820673
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of immunotherapy with methanol extraction residue (MER) of bacillus Calmette-Guérin.
Richman SP; Gutterman JU; Hersh EM; Burgess MA; Mavligit GM
Cancer Treat Rep; 1977; 61(3):471-2. PubMed ID: 872144
[No Abstract] [Full Text] [Related]
10. Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
Ramseur WL; Richards F; Muss HB; Rhyne L; Cooper MR; White DR; Stuart JJ; Spurr CL
Cancer Treat Rep; 1978 Jul; 62(7):1085-7. PubMed ID: 356970
[TBL] [Abstract][Full Text] [Related]
11. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
Vaage J
Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG.
Britell JC; Ahmann DL; Bisel HF; Frytak S; Ingle JN; Rubin J; O'Fallon JR
Cancer Clin Trials; 1979; 2(4):345-50. PubMed ID: 394870
[TBL] [Abstract][Full Text] [Related]
13. A preliminary report on the effects of methanol extraction residue of BCG (MER) on cancer patients.
Robinson E; Bartal A; Cohen Y; Haasz R
Br J Cancer; 1975 Jul; 32(1):1-4. PubMed ID: 1100088
[TBL] [Abstract][Full Text] [Related]
14. MER immunotherapy and combination chemotherapy for advanced, recurrent Hodgkin's disease. Cancer and Leukemia Group B study.
Vinciguerra V; Coleman M; Pajak TF; Rafla S; Stutzman L; Gomez G; Weil M; Brunner K; Cuttner J; Nissen N; Leventhal B; Gottlieb A
Cancer Clin Trials; 1981; 4(2):99-105. PubMed ID: 7018726
[TBL] [Abstract][Full Text] [Related]
15. Preclinical study of iv administration of the methanol extraction residue of bacillus Calmette-Guérin.
Vogl SE; Lumb G; Bekesi JG; Holland JF
Cancer Treat Rep; 1977 Aug; 61(5):901-3. PubMed ID: 329984
[No Abstract] [Full Text] [Related]
16. Procarbazine, vinblastine, and actinomycin D in stage III and IV melanoma with or without methanol-extracted residue of Bacillus Calmette-Guérin.
Kostinas JE; Leone LA; Cuttner J; Vinciguerra V; Green M; De Bellis R; Pajak TF
Cancer Treat Rep; 1979 Feb; 63(2):197-200. PubMed ID: 376132
[TBL] [Abstract][Full Text] [Related]
17. Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer.
Wile AG; Sparks FC; Morton DL
Cancer Res; 1977 Jul; 37(7 Pt 1):2251-6. PubMed ID: 324610
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of bovine cutaneous delayed-type hypersensitivity (DTH) to various test antigens and a mitogen using several adjuvants.
Hernández A; Yager JA; Wilkie BN; Leslie KE; Mallard BA
Vet Immunol Immunopathol; 2005 Mar; 104(1-2):45-58. PubMed ID: 15661330
[TBL] [Abstract][Full Text] [Related]
19. Local reaction to gingival injections of MER/BCG in guinea pigs.
Anavi Y; Bartal A; Kerner V; Gutman D
J Oral Surg; 1979 Jul; 37(7):467-70. PubMed ID: 286760
[TBL] [Abstract][Full Text] [Related]
20. A technique for intensifying BCG sensitivity.
Parmett SR; Klein E
J Med; 1975; 6(3-4):213-6. PubMed ID: 1104733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
